Interpreting Triglycerides: A National Cross‐Sectional Review of Laboratory Reporting Practices Authors: Jeff R Ma, Sean Tan, Gerald F Watts, Nick S R Lan, Robert Hungerford, Peter J Psaltis, Jessica A Marathe, Stephen J Nicholls, Adam J Nelson Published: 2026 Background Hypertriglyceridaemia affects nearly one in five Australians and has implications across two distinct risk domains [1]. Mild‐to‐moderate elevations reflect the presence of triglyceride‐rich lipoproteins and their atherogenic remnants, which impart additional atherosclerotic cardiovascular disease (ASCVD) risk [2], and form part of the cardiometabolic phenotype of metabolic dysfunction‐associated steatotic liver disease. Severe‐to‐extreme hypertriglyceridaemia increases the risk of pancreatitis [3]. At triglyceride concentrations over 2.0 mmol/L, Friedewald‐calculated low‐density lipoprotein cholesterol (LDL‐C) may be underestimated [3], necessitating consideration of direct LDL‐C, non‐high‐density lipoprotein cholesterol (non‐HDL‐C) or apolipoprotein B (apoB) to better reflect atherogenic burden [4]. International guidelines recommend flagging fasting triglycerides ≥ 1.7 mmol/L, non‐fasting triglycerides ≥ 2.0 mmol/L and concentrations ≥ 5.6 mmol/L which define severe hypertriglyceridaemia and warrant assessment of pancreatitis risk [2, 3, 5]. Despite guideline recommendations, hypertriglyceridaemia management remains incompletely implemented [6]. One potential barrier is heterogenous lipid reporting, which could impair recognition of secondary metabolic diseases and delay treatment. Variation in lipid reporting practices is not new. An informal 2006 Australian survey identified seven triglyceride upper reference limits [7]. A 2020 Canadian review similarly found wide variation, with only 56% of laboratories referencing the 2016 Canadian Cardiovascular Society guideline and 36% reporting interest in harmonisation [8]. Australian harmonisation guidance proposed a desirable fasting triglyceride concentration < 1.5 mmol/L in 2007, whereas the 2018 Australasian Association for Clinical Biochemistry (AACB) recommended a 2.0 mmol/L decision limit and displaying fasting status [9, 10]. However, the uptake remains unknown. Methods A cross‐sectional national review of triglyceride reporting practices among Australian chemical pathology laboratory networks was performed. Eligible networks were identified using the official list of pathology services accredited by the Royal College of Pathologists of Australasia (RCPA). All accredited sites performing chemical pathology testing across Australian States and self‐governing Territories were screened. Both public and nationwide private laboratory networks were included. Unaccredited laboratories and small regional private providers were excluded, as the study mainly aimed to characterise national reporting patterns. A network comprised of one or more laboratories using the same organisational structure and reporting framework. For networks containing multiple laboratories, one representative dataset was collected. Eligible networks were contacted by email or telephone and invited to participate. The lead author collected structured responses from laboratory directors or nominated representatives and conducted clarifying interviews when required. Participants were invited to provide representative de‐identified reports or internal templates at their discretion. These were cross‐checked against correspondence and interviews. Participation was voluntary, and all data were anonymised at the pathology‐provider level. A structured data‐collection form captured (1) triglyceride upper reference limits; (2) fasting‐status requirements and display on reports; and (3) the presence and threshold of severe hypertriglyceridaemia or acute pancreatitis warnings. Descriptive statistics summarised laboratory characteristics and reporting practices. The study was deemed negligible risk and approved through an alternative review pathway. Results Eighteen networks met inclusion criteria from the RCPA‐accredited provider list accessed on 8 October 2024. All were contacted by November 2024 and 17 participated (Table 1). Networks represented all eight Australian states and territories: Six statewide public networks, eight individual public hospital networks and three national private networks. All provided written responses and at least one de‐identified patient report; five completed clarifying telephone interviews. No discrepancies were identified between submitted reports and responses. TABLE 1De‐identified laboratory network‐level summary of triglyceride reporting practices.Pathology providerNetwork typeTg upper limit (mmol/L)Fasting status displayedFasting status display locationAcute pancreatitis warningTg threshold to trigger warning (mmol/L)1Public1.5YesTop of lipid panelNo2Private1.7YesTop of lipid panelYes103Public1.7YesTop of lipid panelYes204Public1.7YesAs a commentNo5Public2YesTop of lipid panelYes106Public2YesBottom of lipid panelNo7Private2NoN/ANo8Public2YesBottom of lipid panelYes129Public2NoN/AYes1010Public2YesIn brackets next to resultsNo11Public2YesTop of lipid panelYes1012Public2YesTop of lipid panelYes1013Public2YesTop of lipid panelYes1214Public2NoN/ANo15Public2NoN/ANo16Private2.1YesTop of lipid panelYes1017Public2.1NoN/ANoAbbreviations: N/A, not applicable; Tg, triglyceride. De‐identified laboratory network‐level summary of triglyceride reporting practices. Abbreviations: N/A, not applicable; Tg, triglyceride. Four different triglyceride upper reference limits or decision limits were identified, ranging from 1.5 to 2.1 mmol/L (Figure 1). One network (6%) used the 2007 recommended fasting limit of 1.5 mmol/L. Against the 2018 AACB harmonised lipid reporting recommendation, 11 networks (65%) used a 2.0 mmol/L decision limit, 12 (71%) displayed fasting status and 7 (41%) did both. Among the seven networks which referenced the 2018 recommendations, triglyceride decision limits still differed, ranging from 1.7 to 2.1 mmol/L. Distribution of triglyceride decision limits across participating pathology networks. Bars represent the number of networks using each decision limit. Colours identify the 2007 Australian Pathology Lipid Interest Group desirable value of 1.5 mmol/L* [9], the 2019 European Society of Cardiology/European Atherosclerosis Society and 2026 American College of Cardiology/American Heart Association recommended fasting threshold of 1.7 mmol/L† [3, 4], the 2018 Australasian Association of Clinical Biochemistry harmonised lipid reporting decision limit of 2.0 mmol/L^ [10] and an observed alternative value of 2.1 mmol/L. Among the 12 networks displaying fasting status, eight placed it at the top of the panel, two at the bottom, one within an interpretive comment and one in brackets beside the result. No network reported different reference limits according to fasting status. Nine networks included severe hypertriglyceridaemia or acute pancreatitis warnings, with triggering thresholds of 10.0–20.0 mmol/L. Eight routinely notified clinicians of markedly elevated triglyceride results. Discussion Variation in triglyceride reference limits may appear numerically modest, but the inconsistency likely represents a missed opportunity for the treating clinician to identify atherogenic dyslipidaemia and intensify preventive care. While the definition of ‘normal’ triglyceride remains contested, values above 1.7 mmol/L are generally associated with higher ASCVD risk [2, 3, 4], yet most laboratories used the upper limit of 2.0 mmol/L or higher. In this context, a triglyceride result of 1.9 mmol/L would be reported as ‘normal’ by most laboratories, potentially providing false reassurance to patients who receive a copy of their pathology report, and discouraging clinicians from recommending lifestyle modification or considering a therapy such as icosapent ethyl, which has demonstrated cardiovascular benefit [1]. The 2022–2024 Australian National Health Measures Survey showed that 14.8% of adults with fasting measurements had triglyceride concentrations of 1.5 to < 2.0 mmol/L, similar to the 14.5% with concentrations ≥ 2.0 mmol/L. Assuming an approximately log‐normal distribution, an estimated 8% of Australian adults (approximately 1.6 million people) may lie within 1.7 to < 2.0 mmol/L [11]. Inconsistent fasting‐status display also reduces interpretability. Triglyceride concentrations rise by approximately 0.3 mmol/L within 1–6 h after habitual meals [5], so reports omitting fasting status may not indicate whether the 1.7 or 2.0 mmol/L threshold applies. Relevant therapies may therefore be erroneously withheld when a fasting triglyceride was interpreted using non‐fasting thresholds. A fasting triglyceride concentration of 1.7–5.6 mmol/L is also required to meet Australian subsidy criteria for icosapent ethyl. Only nine networks included pancreatitis risk warnings with highly variable triggering thresholds (10.0 to 20.0 mmol/L), despite pancreatitis risk becoming a management concern at triglyceride concentrations greater than 5.6 mmol/L [4]. Hypertriglyceridaemia‐induced pancreatitis can be life‐threatening but may be prevented through early recognition. Nevertheless, fewer than half of surveyed networks routinely notified the requesting clinician. Effective management strategies exist, including intensive dietary fat restriction, statins, fish oil and fibrates; however, these individuals need to be referred to specialised clinics where targeted therapies, such as plozasiran and olezarsen, can be considered [4]. Failure to flag markedly abnormal results risks delaying intervention until pancreatitis has occurred. Although clinicians should not rely solely on pathology comments to make management decisions, laboratory reports remain a major interface through which biochemical information is framed and communicated, particularly as patients increasingly access their own results [12]. This is especially relevant for triglycerides, where interpretation depends on fasting status and cardiometabolic context. Limitations First, unaccredited and small regional private laboratories were excluded which may limit generalisability. However, these providers may use localised reporting systems and likely add further variability rather than less. Second, the number and range of de‐identified reports or templates varied by provider, although responses were cross‐checked with submitted reports where available. Third, reporting practices may vary between individual laboratories within larger networks despite shared reporting frameworks. Finally, this study assessed reporting practices only and did not measure the extent to which variability directly affected prescribing patterns, repeat testing in the fasting state or pancreatitis outcomes. Conclusion Triglyceride reporting practices vary across Australian pathology providers. National harmonisation may reduce conflicting messages, improve recognition of secondary metabolic disease and support timely prevention of hypertriglyceridaemia‐induced pancreatitis. Funding The authors have nothing to report. Disclosure This article has not been published previously and is currently not being considered for publication elsewhere. Conflicts of Interest S.T.: Consulting fees from Cipla, Novartis and Pfizer. GFW: Honoraria for advisory boards, lectures or research grants from Amgen, Arrowhead, CSL Seqirus, Esperion, Novartis, Novo Nordisk and Sanofi. N.S.R.L.: Research funding from Sanofi as part of a Clinical Fellowship in Endocrinology and Diabetes, education support from Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, CSL Seqirus, Eli Lilly, Novartis, Novo Nordisk and Pfizer, speaker honoraria from Amgen, AstraZeneca, Boehringer Ingelheim, CSL Seqirus, Eli Lilly, Menarini, Novartis, Novo Nordisk and Sanofi, and has participated in advisory boards for Eli Lilly. R.H.: Speaker honoraria for AstraZeneca, Novartis, Novo Nordisk. P.J.P.: Research support from Abbott Vascular, Amgen and Biotronik, consulting fees from Amgen, Esperion, Eli Lilly, Novartis, Novo Nordisk and Sanofi, and speaker honoraria from Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Merck Schering‐Plough, Novartis, Novo Nordisk, Pfizer and Sanofi, and is a non‐executive board director of Corcillum Systems. S.J.N.: Grant/research support from AstraZeneca, NewAmsterdam Pharma, Amgen, Anthera, Cyclarity, Eli Lilly, Esperion, Novartis, Cerenis, The Medicines Company, Resverlogix, InfraReDx, Roche, Sanofi‐Regeneron and LipoScience; and was a consultant for Abcentra, AstraZeneca, Amarin, Akcea, Eli Lilly, Anthera, Omthera, Merck, Takeda, Resverlogix, Sanofi‐Regeneron, CSL Behring, Esperion, Boehringer Ingelheim, Daiichi Sankyo, Scribe Therapeutics, Silence Therapeutics, CSL Seqirus and Vaxxinity, and holds stock options for NewAmsterdam Pharma. A.J.N.: Research support from AstraZeneca, Amgen, Eli Lilly and Novartis; and is a consultant for Amgen, AstraZeneca, Boehringer Ingelheim, CSL Sequiris, Eli Lilly, GlaxoSmithKline, Novartis, Novo Nordisk, Sanofi Pasteur and Vaxxinity. The other authors declare no conflicts of interest. Acknowledgements Open access publishing facilitated by Adelaide University, as part of the Wiley ‐ Adelaide University agreement via the Council of Australasian University Librarians. Ma J. R., Tan S., Watts G. F., et al., “Interpreting Triglycerides: A National Cross‐Sectional Review of Laboratory Reporting Practices,” Diabetes, Obesity and Metabolism 28, no. 11 (2026): 10895–10898, 10.1111/dom.71254. Handling Editor: Richard Donnelly Data Availability Statement The data that support the findings of this study are available on request from the corresponding author. The data are not publicly available due to privacy or ethical restrictions. References Associated Data Data Availability Statement The data that support the findings of this study are available on request from the corresponding author. The data are not publicly available due to privacy or ethical restrictions.